Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Professeur THIERRY THOMAS

📍 Saint-Priest-en-Jarez (42)HospitalierRPPS 10003097648
📊 Reconnaissance scientifique : 50/100📝 359 articles publiés📚 HAL (8)

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

50

h articles cités ≥ h fois chacun. Un h de 50 = 50 publications avec 50+ citations.

Citations

10 774

Publications

359

i10-index

130

Thématiques principales

  • Bone health and osteoporosis research ×147
  • Bone health and treatments ×59
  • Bone Metabolism and Diseases ×58
  • Rheumatoid Arthritis Research and Therapies ×41
  • Hip and Femur Fractures ×41

Affiliations FR : Inserm · Hôpital Nord · Centre Hospitalier Universitaire de Saint-Étienne

Voir sur OpenAlex ↗🆔 ORCID 0000-0001-5959-9183

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

  • HOPITAL NORD - CHU42

    Avenue ALBERT RAIMOND, 42277 Saint-Priest-en-Jarez

    ☎ 0477828002Hospitalier

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (2)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

  • Le CHU de Saint-Etienne poursuit sa réorganisation sur deux sites - mesinfos

    📰 mesinfos · 16/01/2026

    <a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOa1hhd2M4VGFRUmFhMGlrWTJTU3lXTHpKMEtzc2ZJb2JqNklzN0xFbFE1dWFjSGU5NHhNODBjLWZtNDNseEVDNkVHLXB5YVpiMEJtYml3Mm9nbHpuNjVpd2dUVTdXN2tvWFA2RXRWQkpFZWktazlSd25jNnpCX2Q3aDdnbkJMa08zYS1LbDNwUUx0akI5N0I2aWpDa25aNDg3dXVDbklCMW5SV3NnQ2Y0LTZXWnZQUVd0?o

  • Une clinique du sport dans la Loire - Le Pays Roannais

    📰 Le Pays Roannais · 06/10/2022

    <a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNWVBWeEpfNTZEeGY5dlp1WkdMcVFyUVVrTTI1QnhjdXFaN0lRSFpnTjVCaGpHclF5ZlhUQlQtWERvV2dmZ2dFcEd3Wm9VUDU2WXdJV3czUXdweDVtbWpEN214OExSVGdFSnVjdlBKX045cHgwbV8zSmRuaUh0MXVOeThfN3E1MHppWW1CdDlCS1pRUTZiR1VOQVFTQzRFbFda?oc=5" target="_blank">Une cliniqu

Top publications · les plus citées

  • 1
    Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023

    📚 411 citations🎯 RCR 91.31Top 0% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    ABSTRACT In this international study, we examined the incidence of hip fractures, postfracture treatment, and all‐cause mortality following hip fractures, based on demographics, geography, and calendar year. We used patient‐level healthcare data from 19 countries and regions to identify patients aged 50 years and older hospitalized with a hip fracture from 2005 to 2018. The age‐ and sex‐standardized incidence rates of hip fractures, post‐hip fracture treatment (defined as the proportion of patients receiving anti‐osteoporosis medication with various mechanisms of action [bisphosphonates, denosumab, raloxifene, strontium ranelate, or teriparatide] following a hip fracture), and the all‐cause mortality rates after hip fractures were estimated using a standardized protocol and common data model. The number of hip fractures in 2050 was projected based on trends in the incidence and estimated future population demographics. In total, 4,115,046 hip fractures were identified from 20 databases. The reported age‐ and sex‐standardized incidence rates of hip fractures ranged from 95.1 (95% confidence interval [CI] 94.8–95.4) in Brazil to 315.9 (95% CI 314.0–317.7) in Denmark per 100,000 population. Incidence rates decreased over the study period in most countries; however, the estimated total annual number of hip fractures nearly doubled from 2018 to 2050. Within 1 year following a hip fracture, post‐hip fracture treatment ranged from 11.5% (95% CI 11.1% to 11.9%) in Germany to 50.3% (95% CI 50.0% to 50.7%) in the United Kingdom, and all‐cause mortality rates ranged from 14.4% (95% CI 14.0% to 14.8%) in Singapore to 28.3% (95% CI 28.0% to 28.6%) in the United Kingdom. Males had lower use of anti‐osteoporosis medication than females, higher rates of all‐cause mortality, and a larger increase in the projected number of hip fractures by 2050. Substantial variations exist in the global epidemiology of hip fractures and postfracture outcomes. Our findings inform possible actions to reduce the projected public health burden of osteoporotic fractures among the aging population. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

  • 2
    Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

    BMJ (Clinical research ed.) · 2023

    📚 155 citations🎯 RCR 25.67Top 1% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Objective To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. Design Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. Data sources Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. Eligibility criteria for selecting studies Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. Results The results were based on 69 trials (&gt;80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. Conclusions The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. Systematic review registration PROSPERO CRD42019128391.

  • 3
    Management of patients at very high risk of osteoporotic fractures through sequential treatments

    Aging clinical and experimental research · 2022

    📚 80 citations🎯 RCR 10.11Top 3% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractOsteoporosis care has evolved markedly over the last 50 years, such that there are now an established clinical definition, validated methods of fracture risk assessment and a range of effective pharmacological agents. Currently, bone-forming (anabolic) agents, in many countries, are used in those patients who have continued to lose bone mineral density (BMD), patients with multiple subsequent fractures or those who have fractured despite treatment with antiresorptive agents. However, head-to-head data suggest that anabolic agents have greater rapidity and efficacy for fracture risk reduction than do antiresorptive therapies. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) convened an expert working group to discuss the tools available to identify patients at high risk of fracture, review the evidence for the use of anabolic agents as the initial intervention in patients at highest risk of fracture and consider the sequence of therapy following their use. This position paper sets out the findings of the group and the consequent recommendations. The key conclusion is that the current evidence base supports an “anabolic first” approach in patients found to be at very high risk of fracture, followed by maintenance therapy using an antiresorptive agent, and with the subsequent need for antiosteoporosis therapy addressed over a lifetime horizon.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal28

▼

Revue générale7

▼

Épidémiologie & registres4

▼

Essai clinique4

▼

Pharmacovigilance3

▼

Revue / méta-analyse3

▼

csDMARDs2

▼

Qualité de vie / PROMs2

▼

Économie santé1

▼

IA en rhumatologie1

▼

Lupus1

▼

Sjögren1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.